KLONOPIN RAPIDLY DISINTEGRATING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).

How it works

Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4-mediated reduction and glucuronidation; minor pathways include N-acetylation and oxidation.
Excretion	Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Half-life	Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Protein binding	85-90% bound to albumin.
Volume of Distribution	1.8-3.0 L/kg (extensive distribution into tissues; high lipid solubility).
Bioavailability	Oral (rapidly disintegrating tablet): ~90% (rapid and complete absorption, not affected by food; equivalent to conventional oral tablets).
Onset of Action	Oral (rapidly disintegrating tablet): 20-60 minutes for anxiolytic effect; 30-60 minutes for anticonvulsant effect (peak plasma concentration at 1-2 hours).
Duration of Action	Anxiolytic: 6-12 hours; anticonvulsant: 12-24 hours (due to long half-life, once or twice daily dosing provides sustained effect; tolerance may develop with chronic use).

Classification & Brands

Dosing & administration

0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.

Dosage form	TABLET, ORALLY DISINTEGRATING
Renal impairment	Clcr 10-50 mL/min: reduce to 75% of normal dose; Clcr <10 mL/min: reduce to 50% of normal dose.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: reduce dose by 50% and titrate cautiously.
Pediatric use	For seizure disorders (age <10 years or <30 kg): 0.01-0.03 mg/kg/day divided three times daily, titrate to 0.1-0.2 mg/kg/day. Not established for anxiety disorders.
Geriatric use	Initiate at 0.25 mg twice daily, titrate slowly to avoid oversedation, confusion, and fall risk. Maximum dose often limited to 2 mg/day.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).

Breastfeeding	Clonazepam is excreted into breast milk. Milk-to-plasma ratio approximately 0.7. Monitor infant for sedation, poor feeding, and weight gain. Avoid use if possible; if necessary, use lowest effective dose and monitor infant closely.
Teratogenic Risk	Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, cardiac defects, and neural tube defects. Late third trimester: Risk of neonatal withdrawal syndrome (irritability, tremors, hypertonia) and floppy infant syndrome (hypotonia, lethargy, poor feeding).

Warnings & precautions

■ FDA Black Box Warning

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to clonazepam or other benzodiazepines; history of allergic reaction to any component of the formulation; narrow-angle glaucoma; severe hepatic impairment; concurrent use with opioids except in limited circumstances.

Clinical Precautions

Precautions

Risk of dependence and withdrawal symptoms; tolerance may develop; concomitant use with CNS depressants; risk of respiratory depression; caution in hepatic impairment; may cause anterograde amnesia; not recommended in severe hepatic impairment; avoid abrupt discontinuation; may impair driving and other activities.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

KLONOPIN RAPIDLY DISINTEGRATING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).

How it works

Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4-mediated reduction and glucuronidation; minor pathways include N-acetylation and oxidation.
Excretion	Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Half-life	Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Protein binding	85-90% bound to albumin.
Volume of Distribution	1.8-3.0 L/kg (extensive distribution into tissues; high lipid solubility).
Bioavailability	Oral (rapidly disintegrating tablet): ~90% (rapid and complete absorption, not affected by food; equivalent to conventional oral tablets).
Onset of Action	Oral (rapidly disintegrating tablet): 20-60 minutes for anxiolytic effect; 30-60 minutes for anticonvulsant effect (peak plasma concentration at 1-2 hours).
Duration of Action	Anxiolytic: 6-12 hours; anticonvulsant: 12-24 hours (due to long half-life, once or twice daily dosing provides sustained effect; tolerance may develop with chronic use).

Classification & Brands

Dosing & administration

0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.

Dosage form	TABLET, ORALLY DISINTEGRATING
Renal impairment	Clcr 10-50 mL/min: reduce to 75% of normal dose; Clcr <10 mL/min: reduce to 50% of normal dose.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: reduce dose by 50% and titrate cautiously.
Pediatric use	For seizure disorders (age <10 years or <30 kg): 0.01-0.03 mg/kg/day divided three times daily, titrate to 0.1-0.2 mg/kg/day. Not established for anxiety disorders.
Geriatric use	Initiate at 0.25 mg twice daily, titrate slowly to avoid oversedation, confusion, and fall risk. Maximum dose often limited to 2 mg/day.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KLONOPIN RAPIDLY DISINTEGRATING (KLONOPIN RAPIDLY DISINTEGRATING).

Breastfeeding	Clonazepam is excreted into breast milk. Milk-to-plasma ratio approximately 0.7. Monitor infant for sedation, poor feeding, and weight gain. Avoid use if possible; if necessary, use lowest effective dose and monitor infant closely.
Teratogenic Risk	Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, cardiac defects, and neural tube defects. Late third trimester: Risk of neonatal withdrawal syndrome (irritability, tremors, hypertonia) and floppy infant syndrome (hypotonia, lethargy, poor feeding).